Why the HIV epidemic is not over after 30yrs of hard fight

Sunday July 21 2019

 

By The Citizen Reporter @TheCitizenTZ news@thecitizen.co.tz

Fear, stigma and ignorance. That is what defined the HIV epidemic that raged through the world in the 1980s, killing thousands of people who may only have had a few weeks or months from diagnosis to death - if they even managed to be diagnosed before they died.

“With no effective treatment available in the 1980s, there was little hope for those diagnosed with HIV, facing debilitating illness and certain death within years,” says Dr Gottfried Hirnschall, Director of the HIV department at WHO.

David Kirby, an American HIV/Aids activist, photographed age 32 years at his deathbed by Therese Frare. He is surrounded by his father, sister and niece. The image was first published in 1990 in Life magazine, who called it “The photo that changed the face of Aids”.

1 December 2018 marks the 30th anniversary of World Aids Day – a day created to raise awareness about HIV and the resulting Aids epidemics. Since the beginning of the epidemic, more than 70 million people have acquired the infection, and about 35 million people have died. Today, around 37 million worldwide live with HIV, of whom 22 million are on treatment.

When World Aids Day was first established in 1988, the world looked very different to how it is today. Now, we have easily accessible testing, treatment, a range of prevention options, including pre-exposure prophylaxis of PrEP, and services that can reach vulnerable communities.

In the late 1980s, however, “the outlook for people with HIV was pretty grim,” says Dr Rachel Baggaley, coordinator of HIV testing and prevention at WHO. “Antiretrovirals weren’t yet available, so although we could offer treatment for opportunistic infections there was no treatment for their HIV. It was a very sad and difficult time.”

The first World Aids Day

At the beginning of the 1980s, before HIV had been identified as the cause of Aids, the infection was thought to only affect specific groups, such as gay men in developed countries and people who inject drugs. The HIV virus was first isolated by Dr Françoise Barré-Sinoussi and Dr Luc Montagnier in 1983 at the Institut Pasteur. In November that year, WHO held the first meeting to assess the global Aids situation and initiated international surveillance. It was then that the global health community understood that HIV could also spread between heterosexual people, through blood transfusions, and that infected mothers could transmit HIV to their babies.

With increasing awareness that Aids was emerging as a global public health threat, the first International Aids Conference was held in Atlanta in 1985.

“In those early days, with no treatment on the horizon, extraordinary prevention, care and awareness-raising efforts were mobilized by communities around the world – research programmes were accelerated, condom access was expanded, harm reduction programmes were established and support services reached out to those who were sick,” says Dr Andrew Ball, senior adviser on HIV at WHO.

WHO established the Special Programme on Aids in February 1987, which was to become the Global Programme on Aids (GPA) under the leadership of the charismatic Dr Jonathan Mann with the aim of driving research and country responses.

In 1988, two WHO communications officers, Thomas Netter and James Bunn, put forward the idea of holding an annual World Aids Day, with the aim of increasing HIV awareness, mobilising communities and advocating for action worldwide. This December is the 30th anniversary of World Aids Day, with the theme: “Know Your Status”.

It wasn’t until 1991 that the HIV movement was branded with the iconic red ribbon. At that time New York based artists from the Visual Aids Artists’ Caucus created the symbol, choosing the colour for its “connection to blood and the idea of passion—not only anger, but love...” This was the very first disease-awareness ribbon, a concept that would later be adopted by many other health causes.

Scaling up treatment

The effort to develop effective treatment for HIV is remarkable in its speed and success. Clinical trials of antiretrovirals (ARVs) began in 1985 – the same year that the first HIV test was approved – and the first ARV was approved for use in 1987. However, a single drug was found to have only short-term benefits.

By 1995, ARVs were being prescribed in various combinations. A breakthrough in the HIV response was announced to the world at the 11th International Aids Conference in Vancouver when the success of as “highly active antiretroviral treatment” (HAART) – a combination of three ARVs reported to reduce Aids-related deaths by between 60 and 80 per cent.

Effective treatment had arrived, and within weeks of the announcement, thousands of people with HIV had started HAART. However, not everybody would benefit from this life-saving innovation. Because of the high cost of ARVs, most low- and middle-income countries could not afford to provide treatment through their public programmes.

Such inequities generated outrage in communities and demands for affordable drugs and public treatment programmes. Generic manufacturing of ARVs would only start in 2001 providing bulk, low-cost access to ARVs for highly affected countries, particularly in sub-Saharan Africa, where by 2000, HIV had become the leading cause of death.

During the first decade of the response, it became increasingly evident that an effective HIV response required a multisectoral response: to tackle marginalization, stigma and discrimination, to address the economic, social and security threats of a rapidly expanding pandemic, and to generate the necessary human and financial resources to sustain worldwide action.

In 1996, UNAIDS (the Joint United Nations Programme on HIV/Aids) was established to lead a multisectoral response. In 2000, the United Nations General Assembly adopted the Millennium Development Goals, which committed to ‘halting and reversing the Aids epidemic by 2015’. In 2002, The Global Fund to Fight Aids, Tuberculosis and Malaria was established as a financing mechanism to attract and invest resources to end these three diseases.

A year later, in 2003, the United States President’s Emergency Plan for Aids Relief (PEPFAR) was launched, the largest ever bilateral international health initiative.

WHO announced the “3 by 5” initiative with the aim of providing HIV treatment to 3 million people in low- and middle-income countries by 2005. “The ‘3 by 5’ initiative was the most ambitious public health programme ever launched, which would increase 15-fold the number of people receiving life-saving treatment in some of the poorest countries of the world, in just three years”, says Dr Ball.

Despite continued, unprecedented expansion of access to HIV treatment in the early 2010s, there was growing concern that we weren’t moving fast enough, and that we weren’t getting ahead of the epidemic. In 2014, the “90-90-90” targets were launched to galvanise further action.

By 2020, the targets were that: 90 per cent of all people living with HIV will know their HIV status; 90 per cent of all people diagnosed with HIV infection will receive sustained antiretroviral therapy; and 90 per cent of all people receiving antiretroviral therapy will achieve viral suppression.

WHO and HIV: 30-year timeline

As committed as the global health community was, the dedication of HIV activists and advocates in pushing for patient-driven care, improving access to new drugs, and expanding funding for both HIV care and research, has been unparalleled in almost any other disease field. The movement was characterised by public rallies, and innovative awareness raising campaigns, including art by significant artists such as Keith Haring (whose HIV awareness artwork is the cover image for this Spotlight).

As a result of these commitments from the global health community, the world has seen extraordinary successes in rolling out treatment and care. By 2017, over 75 per cent of people (28 million) estimated to be living with HIV were able to access testing.

“Life has really changed over the past 30 years. Testing is now available widely in most countries. Increasingly countries are also offering self-testing. Self-testing can be empowering – if people are positive for HIV, they can decide to get treatment as well as prevention. If they are negative, they can get support for prevention,” says Dr Baggaley.

Preventing infection

Condoms have been a basic but critical tool in prevention. In many communities of men who have sex with men, and sex workers, awareness-raising meant that the use of condoms became the norm. However, this messaging is not as strongly pushed now, and a new generation is growing up without being fully aware of the benefits of using condoms, and many countries have shortages.

The introduction of harm-reduction programmes (including needle and syringe programmes and opioid substitution therapy) in a range of cities in the mid to late 1980s prevented and reversed explosive HIV epidemics associated with drug injecting, but such effective public health programmes face legal barriers and a lack of political will in many countries, resulting in very low coverage in most countries. Voluntary medical male circumcision, which provides 60 per cent life-long protection from HIV has been rolled out in high burden countries in East and southern Africa benefitting more than 20 million adolescent boys and men.

In 1994 a study showed that providing antiretrovirals to pregnant women infected by HIV and a short course of treatment for the baby once born reduced transmission rates to below 5 per cent, from 15-45 per cent without treatment. The availability and coverage of ARVs to prevent HIV transmission from mother to children has been remarkable, with an estimated 80% of pregnant women with HIV able to access ARVs globally.

In 2015, WHO recommended the use of ARVs to prevent HIV acquisition – pre-exposure prophylaxis or PrEP – for people who do not have HIV but are at substantial risk. PrEP has contributed to reduce rates of new HIV infections among men who have sex with men, in some settings in high-income countries. However, PrEP is only starting to be available in low- and middle-income countries, where programmes are starting for men who have sex with men and transgender people in all regions, as well as sex workers, adolescent girls and young women in East and Southern Africa.

Ending Aids by 2030

HIV is not an easy virus to defeat. Nearly a million people still die every year from the virus because they don’t know they have HIV and are not on treatment, or they start treatment late. This is despite WHO guidelines in 2015 recommending that all people living with HIV should receive antiretroviral treatment, regardless of their immune status and stage of infection, and as soon as possible after their diagnosis.

In 2017, 1.8 million people were newly infected with HIV. While the world has committed to ending Aids by 2030, rates of new infections and deaths are not falling rapidly enough to meet that target.

One of the biggest challenges in the HIV response has remained unchanged for 30 years: HIV disproportionally affects people in vulnerable populations that are often highly marginalized and stigmatized. Thus, most new HIV infections and deaths are seen in places where certain higher-risk groups remain unaware, underserved or neglected.

About 75 per cent of new HIV infections outside sub-Saharan Africa are in men who have sex with men, people who inject drugs, people in prisons, sex workers, or transgender people, or the sexual partners of these individuals. These are groups who are often discriminated against and excluded from health services. HIV continues to disproportionately affect adolescents and young people in many countries. About a third of new HIV infections are in people aged 15-25 years. In almost all countries, young women aged 15–24 years are three to five times more likely than their male counterparts to have HIV.